Health-related quality of life in patients with solid cancer treated with immune checkpoint inhibitors: the ARON-MOUSEION-18 systematic review and meta-analysis
BACKGROUND: Health-related quality of life (HRQoL) contributes to the value of immune checkpoint inhibitors (ICIs), but assessment and reporting remain heterogeneous. METHODS: This PRISMA 2020-compliant systematic review and meta-analysis was registered in PROSPERO (CRD420261330878). PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched for RCTs of adults with solid tumors comparing ICI-based regimens with non-ICI controls and reporting global HRQoL with the EORTC QLQ-C30 GHS/QoL scale or EQ-5D-3L/5L visual analogue scale (VAS). Pooling required a visit-specific adjusted between-group estimate with a 95% confidence interval (CI) or standard error. Random-effects models (restricted maximum likelihood, Hartung-Knapp adjustment) were used. Clinical relevance was assessed using instrument-specific MID benchmarks. RESULTS: Eighty-two RCTs were included: 42 in the quantitative and 40 in the narrative synthesis, 40 reported EORTC QLQ-C30 GHS/QoL, 10 EQ-5D-3L VAS, and 14 EQ-5D-5L VAS. All pooled trials evaluated anti-PD-1-based regimens. The pooled LSMD for EORTC QLQ-C30 GHS/QoL was 1.78 points (95% CI 0.71-2.86; p = 0.002; I2 =71.9%). Neither EQ-5D VAS differ significantly. Most trial-level estimates were below the MID, and no trial showed clinically meaningful deterioration. Favorable estimates were concentrated in open-label active-control, advanced/metastatic and lung cancer trials. CONCLUSION: Anti-PD-1-based therapy results in no clinically important difference in global HRQoL compared with non-ICI controls: the small average advantage is below the MID and concentrated in open-label active-control trials. Interpretation is shaped by trial design, comparator, setting, assessment timing, and incomplete PRO reporting. Standardized PRO reporting is needed across cancer settings and ICI classes.
Authors
- Francesco Ciccimarra (ORCID: https://orcid.org/0009-0009-7321-0950)
- Gerardo Cazzato (ORCID: https://orcid.org/0000-0003-0325-4316)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Mohadeseh Motamed‐Jahromi (ORCID: https://orcid.org/0000-0001-6025-4879)
- Pastore Vito
- Lorenza Maistrello (ORCID: https://orcid.org/0000-0003-2955-4376)
- Enes Erul (ORCID: https://orcid.org/0000-0002-2487-2087)
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Elsa Vitale (ORCID: https://orcid.org/0000-0002-9738-3479)
- Brigida Anna Maiorano (ORCID: https://orcid.org/0000-0001-5423-3158)
- Anna Albano (ORCID: https://orcid.org/0000-0001-7217-6310)
- Alessandro Rizzo (ORCID: https://orcid.org/0000-0003-1990-0490)
- Oronzo Brunetti (ORCID: https://orcid.org/0000-0002-7014-6828)
- Patrizia Nardulli (ORCID: https://orcid.org/0000-0002-2240-5186)
- Chiara Paciolla (ORCID: https://orcid.org/0009-0008-4276-6991)
Institutions
- Ankara University (TR)
- Vita-Salute San Raffaele University (IT)
- Azienda USL di Bologna (IT)
- IRCCS San Camillo Hospital (IT)
- Istituto Tumori Bari (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fasa University of Medical Sciences (IR)
- Ospedale di Macerata (IT)
- University of Macerata (IT)
- University of Bari Aldo Moro (IT)
- University of Bologna (IT)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1093/jnci/djag431
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00